OBJECTIVES: In France, the Commission for Economic and Public Health Evaluation (CEESP) provides an economic opinion of the incremental cost-effectiveness ratio (ICER) validity. During the last few years, due to the arrival of innovative therapies such as CAR-T cells therapies, onco-hematology is taking an important place in this area.

METHODS: Using Vyoo Agency efficiency database, all CEESP opinions in onco-hematology appraised until May 25, 2023, were reviewed. We consider an opinion valid if there are no mention of major uncertainty or objection. As CEESP doctrine has evolved during the last 2 years, uncertainty was not a discriminant criterion before august 2021. So, the ICER as not validated only if CEESP conclusion is clearly stated that is not retained despite an acceptable methodology.

RESULTS: Among the 34 opinions in onco-hematology, 33 were published (one was not published). These opinions were related to 10 indications, with 27% of them in chronic lymphocytic leukemia and 18% on Multiple Myeloma.

CONCLUSIONS: Onco-hematology is characterized by a low proportion of validated economic opinions and an important variability of the results. These can be related to the specific methodological and clinical background of this area and the increase of CAR-T cells therapies. Indeed, the duration of the simulation, the treatment effect for one-shot therapy and the inclusion of all the comparators (single-arm trials) complicate the modeling.